Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act).
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Issues related to research and development tax amortization in H.R. 2673, S.866 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
Duration: February 8, 2021
to
December 31, 2023
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code
Spending: about $350,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
THE MCMANUS GROUP terminated an engagement in which they represented PTC Therapeutics Inc. on Jan. 20.
Original Filing: 301534008.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act).
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to research and development tax amortization in H.R. 2673, S.866 American Innovation and R&D competitiveness Act of 2023, S.866 - American Innovation and Jobs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516582.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act).
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on July 20, 2023.
Original Filing: 301490425.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022
Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act).
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on April 20, 2023.
Original Filing: 301466881.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022.
Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patients (MVP) Act).
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Supporting the designation of October 23 as "AADC Deficiency Awareness Day".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to research & development tax amortization.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438555.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
H.Res.742 - Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2022
In Q3, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415286.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376-Inflation Reduction Act of 2022.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
H.Res.742 - Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2022
In Q2, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301390347.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
H.Res.742 - Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2022
In Q1, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on April 20, 2022.
Original Filing: 301365307.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
H.Res.742 - Supporting the designation of October 23, 2021, as "AADC Deficiency Awareness Day".
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed tax changes including Sec. 13814 of H.R. 5376 - Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on Jan. 20, 2022.
Original Filing: 301336196.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Proposed tax changes including Sec. 13814 of H.R. 5376 - Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311705.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2021
In Q2, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $30,000. The report was filed on July 20, 2021.
Original Filing: 301284834.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program.
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Education and awareness of rare and ultra rare diseases and patient access to orphan drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2021
In Q1, THE MCMANUS GROUP lobbied for PTC Therapeutics Inc. , earning $20,000. The report was filed on April 20, 2021.
Original Filing: 301264558.xml
Lobbying Issues
Access and coverage of pharmaceuticals in Medicaid program
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate